Literature DB >> 10070029

Effects of arginine vasopressin on cell volume regulation in brain astrocyte in culture.

D Sarfaraz1, C L Fraser.   

Abstract

Astrocytes initially swell when exposed to hypotonic medium but rapidly return to normal volume by the process of regulatory volume decrease (RVD). The role that arginine vasopressin (AVP) plays in hypotonically mediated RVD in astrocytes is unknown. This study was therefore designed to determine whether AVP might play a role in astrocyte RVD. With the use of 3-O-[3H]methyl-D-glucose to determine water space, AVP treatment resulted in significantly increased 3-O-methyl-D-glucose water space within 30 s of hypotonic exposure (P = 0.0001) and remained significantly elevated above baseline (1. 75 microliter/mg protein) at 5 min (P < 0.021). In contrast, in untreated cells, complete RVD was achieved by 5 min. At 30 s, cell volume with AVP treatment was 37% greater than in cells that received no treatment (2.9 vs. 2.26 microliter/mg protein, respectively; P < 0.006). The rate of cell volume increase (dV/dt) over 30 s was highly significant (0.038 vs. 0.019 microliter. mg protein-1. s-1 in the AVP-treated vs. untreated group; P = 0.0004 by regression analysis). Additionally, the rate of cell volume decrease over the next 4.5 min was also significantly greater with vasopressin treatment (-dV/dt = 0.0027 vs. 0.0013 microliter. mg protein-1. s-1; P = 0.0306). The effect of AVP was concentration dependent with EC50 = 3.5 nM. To determine whether AVP action was receptor mediated, we performed RVD studies in the presence of the V1-receptor antagonists benzamil and ethylisopropryl amiloride and the V2-receptor agonist 1-desamino-8-D-arginine vasopressin (DDAVP). Both V1-receptor antagonists significantly inhibited AVP-mediated volume increase by 40-47% (P < 0.005), whereas DDAVP had no stimulatory effects above control. Taken together, these data suggest that AVP treatment of brain astrocytes in culture appears to increase 3-O-methyl-D-glucose water space during RVD through V1 receptor-mediated mechanisms. The significance of these findings is presently unclear.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10070029     DOI: 10.1152/ajpendo.1999.276.3.E596

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  9 in total

Review 1.  Receptor regulation of osmolyte homeostasis in neural cells.

Authors:  Stephen K Fisher; Anne M Heacock; Richard F Keep; Daniel J Foster
Journal:  J Physiol       Date:  2010-05-24       Impact factor: 5.182

Review 2.  Volume-dependent osmolyte efflux from neural tissues: regulation by G-protein-coupled receptors.

Authors:  Stephen K Fisher; Tooba A Cheema; Daniel J Foster; Anne M Heacock
Journal:  J Neurochem       Date:  2008-06-02       Impact factor: 5.372

3.  A novel role of vasopressin in the brain: modulation of activity-dependent water flux in the neocortex.

Authors:  H Niermann; M Amiry-Moghaddam; K Holthoff; O W Witte; O P Ottersen
Journal:  J Neurosci       Date:  2001-05-01       Impact factor: 6.167

4.  Aquaporin-4 distribution in control and stressed astrocytes in culture and in the cerebrospinal fluid of patients with traumatic brain injuries.

Authors:  Marianna Lo Pizzo; Gabriella Schiera; Italia Di Liegro; Carlo Maria Di Liegro; József Pál; Endre Czeiter; Endre Sulyok; Tamás Dóczi
Journal:  Neurol Sci       Date:  2012-11-10       Impact factor: 3.307

5.  A model of inositol compartmentation in astrocytes based upon efflux kinetics and slow inositol depletion after uptake inhibition.

Authors:  M Wolfson; Y Bersudsky; E Hertz; V Berkin; E Zinger; L Hertz
Journal:  Neurochem Res       Date:  2000-07       Impact factor: 3.996

Review 6.  Emerging therapeutic targets for cerebral edema.

Authors:  Ruchira M Jha; Sudhanshu P Raikwar; Sandra Mihaljevic; Amanda M Casabella; Joshua S Catapano; Anupama Rani; Shashvat Desai; Volodymyr Gerzanich; J Marc Simard
Journal:  Expert Opin Ther Targets       Date:  2022-01-02       Impact factor: 6.797

7.  Changes and effects of plasma arginine vasopressin in traumatic brain injury.

Authors:  W D Huang; J Pan; M Xu; W Su; Y Q Lu; Z J Chen; T Y Jiang; Y M Yang
Journal:  J Endocrinol Invest       Date:  2008-11       Impact factor: 4.256

8.  Branched-chain Ketoacyl Dehydrogenase Deficiency: Maple Syrup Disease.

Authors:  Kevin A. Strauss; D. Holmes Morton
Journal:  Curr Treat Options Neurol       Date:  2003-07       Impact factor: 3.972

9.  Antagonists of the Vasopressin V1 Receptor and of the β(1)-Adrenoceptor Inhibit Cytotoxic Brain Edema in Stroke by Effects on Astrocytes - but the Mechanisms Differ.

Authors:  Leif Hertz; Junnan Xu; Ye Chen; Marie E Gibbs; Ting Du; Leif Hertz; Junnan Xu; Ye Chen; Marie E Gibbs; Ting Du
Journal:  Curr Neuropharmacol       Date:  2014-07       Impact factor: 7.363

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.